ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pembrolizumab, berahyaluronidase alfa drug combination

Also written as “Pembrolizumab (+) Berahyaluronidase alfa” and “Pembrolizumab Formulated with Berahyaluronidase Alfa”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Carcinoma, Squamous Cell, led by Merck.

Furthest: phase 3, since Mar 29, 20188 company-led studies, 7 open or runningNext primary completion: Mar 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck87 open or runningphase 3since Mar 29, 2018Mar 29, 2018Mar 31, 2028phase 2 · NCT06041802

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 29, 2018First study: phase 3 study in Hematologic NeoplasmsFirst studyNCT03486873 · 3,500 planned · United States, Argentina, Australia and more
  2. Aug 18, 2021Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05017012 · 142 enrolled · Chile, Hungary, Japan and more
  3. Jan 27, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05722015 · 377 enrolled · United States, Argentina, Brazil and more
  4. Sep 11, 2023Phase 2 study in Carcinoma, Squamous CellNCT06041802 · 19 enrolled · Japan
  5. Oct 19, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06099782 · 147 enrolled · United States, Argentina, Australia and more
  6. Jan 9, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06212752 · 39 enrolled · Japan
  7. Jul 11, 2024Phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT06504394 · 66 enrolled · United States, Australia, Chile and more
  8. Nov 18, 2024Phase 3 study in Lung NeoplasmsNCT06698042 · 67 enrolled · United States, China, Germany and more

Ahead

  1. Mar 31, 2028Primary completion: phase 2 study in Carcinoma, Squamous CellNCT06041802
  2. Nov 8, 2028Primary completion: phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT06504394
  3. Aug 4, 2043Primary completion: phase 3 study in Hematologic NeoplasmsNCT03486873

TargetBeta

PDCD1 →read by rule
“A fixed-dose co-formulation composed of pembrolizumab, a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1; programmed cell death-1; cluster of differentiation 279; CD279), and berahyaluronidase alfa, a recombinant variant of”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06698042Lung Neoplasms · United States, China, Germany and more3Active, not recruitingMar 12, 202667
NCT06504394Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Chile and more2Active, not recruitingNov 8, 202866
NCT06212752Carcinoma, Non-Small-Cell Lung · Japan3Active, not recruitingNov 6, 202439
NCT06099782Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2Active, not recruitingApr 9, 2025147
NCT06041802Carcinoma, Squamous Cell · Japan2Active, not recruitingMar 31, 202819
NCT05722015Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3Active, not recruitingJul 12, 2024377
NCT05017012Parkinson Disease 4, Autosomal Dominant Lewy Body · Chile, Hungary, Japan and more1CompletedMay 19, 2026142
NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more3RecruitingAug 4, 20433,500

How it is read

Names in the registry

  • “Pembrolizumab (+) Berahyaluronidase alfa”, 6 entries
  • “Pembrolizumab Formulated with Berahyaluronidase Alfa”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.